title: Financial impact of nosocomial infections in the intensive care units of a charitable hospital in Minas Gerais, Brazil.
abstract: OBJECTIVE
  Infections in intensive care units are often associated with a high morbidity and mortality in addition to high costs. An analysis of these aspects can assist in optimizing the allocation of relevant financial resources.
  
  
  METHODS
  This retrospective study analyzed the hospital administration and quality in intensive care medical databases [Sistema de Gestão Hospitalar (SGH)] and RM Janus®. A cost analysis was performed by evaluating the medical products and materials used in direct medical care. The costs are reported in the Brazilian national currency (Real). The cost and length of stay analyses were performed for all the costs studied. The median was used to determine the costs involved. Costs were also adjusted by the patients' length of stay in the intensive care unit.
  
  
  RESULTS
  In total, 974 individuals were analyzed, of which 51% were male, and the mean age was 57±18.24 years. There were 87 patients (8.9%) identified who had nosocomial infections associated with the intensive care unit. The median cost per admission and the length of stay for all the patients sampled were R$1.257,53 and 3 days, respectively. Compared to the patients without an infection, the patients with an infection had longer hospital stays (15 [11-25] versus 3 [2-6] days, p<0.01), increased costs per patient in the intensive care unit (median R$9.763,78 [5445.64 - 18,007.90] versus R$1.093,94 [416.14 - 2755.90], p<0.01) and increased costs per day of hospitalization in the intensive care unit (R$618,00 [407.81 - 838.69] versus R$359,00 [174.59 - 719.12], p<0.01).
  
  
  CONCLUSIONS
  Nosocomial infections associated with the intensive care unit were determinants of increased costs and longer hospital stays. However, the study design did not allow us to evaluate specific aspects of cause and effect.
authors.affiliation: Santa Casa de Belo Horizonte - Belo Horizonte (MG), Brazil. glauciooliveira@santacasabh.org.br
authors.forename: Glaucio de Oliveira
authors.initials: Gde O
authors.lastname: Nangino
authors.forename: Cláudio Dornas de
authors.initials: CD
authors.lastname: Oliveira
authors.forename: Paulo César
authors.initials: PC
authors.lastname: Correia
authors.forename: Noelle de Melo
authors.initials: Nde M
authors.lastname: Machado
authors.forename: Ana Thereza Barbosa
authors.initials: AT
authors.lastname: Dias
references.citation: Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
references.pmid: 16355321
references.citation: Rev Bras Ter Intensiva. 2007 Dec;19(4):414-20
references.pmid: 25310156
references.citation: Infect Control Hosp Epidemiol. 2010 Apr;31(4):365-73
references.pmid: 20184420
references.citation: Crit Care Med. 2001 Jul;29(7):1303-10
references.pmid: 11445675
references.citation: Rev Bras Ter Intensiva. 2012 Jun;24(2):143-50
references.pmid: 23917761
references.citation: Pharmacoeconomics. 2008;26(5):425-34
references.pmid: 18429658
references.citation: Rev Hosp Clin Fac Med Sao Paulo. 2003 Sep-Oct;58(5):254-9
references.pmid: 14666322
references.citation: JAMA. 2009 Dec 2;302(21):2323-9
references.pmid: 19952319
references.citation: Rev Bras Ter Intensiva. 2009 Jun;21(2):113-23
references.pmid: 25303339
references.citation: Rev Bras Ter Intensiva. 2011 Jun;23(2):120-4
references.pmid: 25299711
references.citation: Intensive Care Med. 1998 Oct;24(10):1040-6
references.pmid: 9840237
references.citation: Lancet. 2011 Jan 15;377(9761):228-41
references.pmid: 21146207
references.citation: Infect Control Hosp Epidemiol. 2010 Feb;31(2):177-82
references.pmid: 20001732
references.citation: Am J Med. 1991 Sep 16;91(3B):185S-191S
references.pmid: 1928163
references.citation: Infect Control Hosp Epidemiol. 2009 May;30(5):453-60
references.pmid: 19344266
references.citation: Rev Esp Quimioter. 2008;21 Spec No 1:26-34
references.pmid: 18752077
references.citation: Int J Antimicrob Agents. 2009 Mar;33(3):255-7
references.pmid: 19091516